12,372 trials
Familial Chylomicronemia Syndrome
Primary: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 — 17.6; -76.5 percent change — p=< 0.0001
Hypertriglyceridemia
Primary: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 — -0.9; -71.2 percent change — p=<0.0001
Pain
Primary: Change From Baseline in Pain on Movement (POM) on Day 5 of Treatment as Assessed by a 100 Millimeter (mm) Visual Analogue Scale (VAS) — -42.36; -43.47 mm — p=0.5950
Osteoarthritis, Knee
Primary: Change From Baseline in Average Weekly Pain With Walking (NPRS 0-10) in the Index Knee — -2.84; -3.17 score on a scale — p=0.1904
Major Depressive Disorder
Primary: Early and Sustained (Antidepressant) Response (ESR) Rate — 17; 17; 17 Participants — p=1.000
Obsessive-Compulsive Disorder
Primary: Yale Brown Obsessive Compulsive Scale (Y-BOCS) — -4.24; -1.10 mean change in YBOCS score
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Primary: All-Cause Death: Time to Event — 8.3; 0.1; 8.3; 0.7 percentage of participants — p=<0.001
Squamous Cell Carcinoma (SCC) · Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Primary: Overall Survival (OS) — 11.7; 8.5 Months — p=<0.00001
Helicobacter Pylori Infection
Primary: Percentage of Participants With Successful Helicobacter Pylori (H Pylori) Eradication in Participants Without a Clarithromycin- or Amoxicillin-resistant Strain of H…
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.6; 14.6 months — p=0.003
Smoking Cessation · Nicotine Dependence
Primary: The Treatment Satisfaction Survey — 63.62; 64.67 score on a scale
COVID · COVID-19 · SARS-CoV-2
Primary: Ordinal Outcome Scale - Day 7 — 5; 5; 9; 13 Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Binary Response — 73; 130 Participants — p=<0.001
Actinic Keratoses
Primary: Percentage of Participants With Complete Response at Week 12 — 25.3; 23.0 percentage of participants
Benign Prostatic Hyperplasia
Primary: Operative Time — 101; 126 minutes